tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACRV Stock Latest News

Acrivon Therapeutics announces completion, certification of CLIA certified lab
The FlyAcrivon Therapeutics announces completion, certification of CLIA certified lab
13h ago
ACRV
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
27d ago
ACRV
META
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
PremiumThe Fly
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
1M ago
ACRV
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
PremiumRatings
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
1M ago
ACRV
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
PremiumRatings
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
1M ago
ACRV
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
1M ago
F
AEP
Acrivon Showcases Promising Phase 2b Oncology Data Update
Premium
Company Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
1M ago
8K
ACRV
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
Premium
Market News
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
1M ago
ACRV
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
PremiumCompany Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
1M ago
8K
ACRV
Acrivon Therapeutics announces progress across pipeline
PremiumThe Fly
Acrivon Therapeutics announces progress across pipeline
1M ago
ACRV
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
PremiumThe Fly
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
1M ago
ACRV
Acrivon to provide ACR-368, ACR-2316 clinical data in January
PremiumThe Fly
Acrivon to provide ACR-368, ACR-2316 clinical data in January
2M ago
ACRV
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
PremiumRatingsOptimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
3M ago
ACRV
3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
3M ago
ACRV
DASH
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
Premium
Ratings
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
3M ago
ACRV
Acrivon Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Acrivon Therapeutics Reports Q3 2025 Financial Results
3M ago
ACRV
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
PremiumThe Fly
Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)
3M ago
ACRV
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
PremiumMarket News
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
4M ago
ACRV
VTGN
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications
PremiumCompany Announcements
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications
4M ago
ACRV
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment
PremiumCompany AnnouncementsAcrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment
4M ago
ACRV
Acrivon Therapeutics Highlights Synergy in Updated Presentation
Premium
Company Announcements
Acrivon Therapeutics Highlights Synergy in Updated Presentation
6M ago
8K
ACRV
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
Premium
Ratings
Acrivon Therapeutics, Inc.: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
6M ago
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >